Transgene S.A.
TNG.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €6 | €8 | €3 | €10 |
| % Growth | -19.6% | 152.7% | -68.7% | – |
| Cost of Goods Sold | €34 | €30 | €32 | €33 |
| Gross Profit | -€28 | -€22 | -€29 | -€23 |
| % Margin | -439.6% | -274.5% | -929% | -229.1% |
| R&D Expenses | €34 | €30 | €32 | €33 |
| G&A Expenses | €0 | €7 | €3 | €3 |
| SG&A Expenses | €0 | €4 | €3 | €3 |
| Sales & Mktg Exp. | €0 | -€3 | €0 | €0 |
| Other Operating Expenses | -€27 | -€25 | -€2 | -€2 |
| Operating Expenses | €8 | €8 | €33 | €34 |
| Operating Income | -€36 | -€30 | -€30 | -€24 |
| % Margin | -561.3% | -380.3% | -956.6% | -235.4% |
| Other Income/Exp. Net | €2 | €8 | -€3 | €4 |
| Pre-Tax Income | -€40 | -€22 | -€33 | -€20 |
| Tax Expense | €0 | €0 | €0 | €0 |
| Net Income | -€34 | -€22 | -€33 | -€20 |
| % Margin | -534.7% | -282.6% | -1,049.6% | -200.2% |
| EPS | -0.29 | -0.22 | -0.33 | -0.22 |
| % Growth | -31.8% | 33.3% | -50% | – |
| EPS Diluted | -0.29 | -0.22 | -0.33 | -0.22 |
| Weighted Avg Shares Out | 117 | 101 | 100 | 91 |
| Weighted Avg Shares Out Dil | 117 | 101 | 100 | 91 |
| Supplemental Information | – | – | – | – |
| Interest Income | €1 | €7 | €0 | €4 |
| Interest Expense | €2 | €0 | €1 | €0 |
| Depreciation & Amortization | €1 | €2 | €2 | €3 |
| EBITDA | -€27 | -€28 | -€30 | -€24 |
| % Margin | -419.5% | -360% | -970.2% | -235.7% |